We can also estimate the fraction of observed proband de novo variants that contribute to TD risk (Iossifov et al., 2014; Sanders et al., 2015) by dividing the difference in theoretical rate by the theoretical rate in probands. Using this approach, we estimate that 51.3% (95% CI 13.7%–89.0%) of de novo LGD and 22.9% (95% CI 4.8%–41.0%) of de novo damaging variants carry TD risk (Table 3). Again, the estimate for de novo LGD variants in TD is similar to that for ASD (45.9%, 95% CI 31.8%–55.5%) (Sanders et al., 2015).
